Ammoxetine Shows Promise as Effective and Well-Tolerated Treatment for Major Depressive Disorder: Insights from a Phase 2 Randomized Trial
Posted inClinical Updates news Psychiatry

Ammoxetine Shows Promise as Effective and Well-Tolerated Treatment for Major Depressive Disorder: Insights from a Phase 2 Randomized Trial

A phase 2 trial in adults with major depressive disorder demonstrated that ammoxetine at 40 mg/d and 60 mg/d significantly improved depressive symptoms compared to placebo and was generally well tolerated, offering a novel treatment option with potentially fewer adverse effects.
Urgent Surgery Versus Fibrinolytic Therapy in Left-Sided Prosthetic Valve Thrombosis: Insights from a Groundbreaking Randomized Trial
Posted inClinical Updates Emergency Medicine General Surgery news

Urgent Surgery Versus Fibrinolytic Therapy in Left-Sided Prosthetic Valve Thrombosis: Insights from a Groundbreaking Randomized Trial

This first randomized trial comparing urgent surgery and fibrinolytic therapy (low-dose t-PA) for symptomatic left-sided prosthetic valve thrombosis finds similar efficacy but higher mortality with surgery and higher residual valve dysfunction with fibrinolysis.
Long-term Stroke Risk in Chinese Adults with Newly Diagnosed Diabetes and Impaired Glucose Tolerance: Insights from the 34-Year Da Qing Diabetes Study
Posted inClinical Updates Diabetes & Endocrinology Neurology news Specialties

Long-term Stroke Risk in Chinese Adults with Newly Diagnosed Diabetes and Impaired Glucose Tolerance: Insights from the 34-Year Da Qing Diabetes Study

A 34-year follow-up of the Da Qing Diabetes Study reveals significantly increased stroke incidence among Chinese adults with newly diagnosed type 2 diabetes and impaired glucose tolerance, highlighting the beneficial impact of lifestyle intervention, particularly in women.